保險經紀商怡安及韋萊韜悅合併計劃告吹
保險經紀商英國怡安集團(Aon)(AON.US)及愛爾蘭韋萊韜悅(Willis Towers Watson)宣佈同終止300億美元合併計劃,並結束與美國司法部的訴訟。怡安集團將向韋萊韜悅支付10億美元終止收購費。
怡安集團及韋萊韜悅分別爲美國第二及第五大商業保險經紀商。兩者原計劃合併後,將取代美國Marsh & McLennan成爲全球最大保險經紀商。但美國司法部入稟阻止,認爲合併將減少市場競爭及導致價格上升,損害再保險經紀、退休計劃及私營退休醫療交換計劃等競爭。
併購雙方早前已提出多項讓步,包括出售怡安集團的美國退休部門、美國退休保健交換計劃及德國退休業務,與及韋萊韜悅全球再保業務。該合併早前通過獲歐盟執委會有條件批準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.